

FIG. 1A




FIG. 1B






FIG. 1C

**FIG. 2****FIG. 3**




FIG. 4




FIG. 5

G3: SC Vaccine




FIG. 6

G7: IT




FIG. 7




FIG. 8A




FIG. 8B

#	n		Group	mRNA dose	mRNA dose	CpG Adjuvant	Delivery vehicle	DV dose
1	10	IT	OVA+CpG	2 μ g/ms	0.1 mg/kg	1 μ g/ms	38 μ g/ms	1.9 mg/kg
2	10	IT	OVA+IL12	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
3	10	IT	Non-coding mRNA + CpG	2 μ g/ms	0.1 mg/kg	1 μ g/ms	38 μ g/ms	1.9 mg/kg
4	10	IT	Non-coding mRNA + IL12	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
5	10	IT	OAV + IL12 + GM-CSG	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
6	10	IM	OVA + CpG	2 μ g/ms	0.1 mg/kg	1 μ g/ms	38 μ g/ms	1.9 mg/kg
7	10	IM	OVA + IL12	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
8	10	IM	Non-coding mRNA + CpG	2 μ g/ms	0.1 mg/kg	1 μ g/ms	38 μ g/ms	1.9 mg/kg
9	10	IM	Non-coding mRNA + IL12	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
10	10	IM	OAV + IL12 + GM-CSG	2 μ g/ms	0.1 mg/kg	-	38 μ g/ms	1.9 mg/kg
11	5	IM	Control	-	-	-	-	-
12	5	IT	Control	-	-	-	-	-

FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 10G




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E






FIG. 13F

**FIG. 14****FIG. 15**




FIG. 16




FIG. 17




FIG. 18





FIG. 19

**FIG. 20**

Treated vs untreated IL12+OVA




FIG. 21

Treated vs untreated IL12




FIG. 22




FIG. 23




FIG. 24

	OVA+CpG	CpG	OVA+IL12	IL12
Response rate Proximal Tumor	50%	30%	70%	0%
Response Rate Distal Tumor	50%	20%	50%	30%
Overall response Both Tumors	20%	20%	40%	0%

FIG. 25





FIG. 26

**FIG. 27**




FIG. 28




FIG. 29

E6E7 + IL12




FIG. 30A

E6E7 + IL12+LIGHT




FIG. 30B

E6E7 + IL12+LIGHT




FIG. 30C

IL12




FIG. 30D

IL12+LIGHT




FIG. 30E

CpG




FIG. 30F




FIG. 31A




FIG. 31B




FIG. 32




FIG. 33




FIG. 34A





FIG. 35A

FIG. 35B

FIG. 35C

**FIG. 34B**




FIG. 35